Nasdaq:US$17.13 (+0.57) | HKEX:HK$27.50 (+0.60) | AIM:£2.52 (+0.02)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 5 Nov 2009

Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans

1 items
a091105